The potential contribution of ranolazine to Torsade de Pointe

Journal of Cardiovascular Disease Research

Volumn 4, Issue 3, 2013, Pages 187-190

  Liu, Zhigang ^a   Williams, Richard B ^a   Rosen, Boaz D ^a  

^a HARBOR HOSPITAL   (United States)

Author keywords

Prolonged QT interval; Ranolazine; Torsade de Pointes

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; AMLODIPINE; ATENOLOL; ATORVASTATIN; BUMETANIDE; CEFTRIAXONE; CIMETIDINE; CLOPIDOGREL; FUROSEMIDE; GLYCERYL TRINITRATE; IPRATROPIUM BROMIDE; ISOSORBIDE; LOSARTAN; MAGNESIUM; MELOXICAM; PANTOPRAZOLE; POTASSIUM CHLORIDE; RANOLAZINE; SALBUTAMOL;

AGED; ARTICLE; CARDIOPULMONARY ARREST; CASE REPORT; DEFIBRILLATION; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DISEASE DURATION; DYSPNEA; FAMILY HISTORY; FEMALE; FEVER; HUMAN; HYPERTENSION; LETHARGY; LUNG CONGESTION; MALAISE; MEDICAL HISTORY; OBESITY; PHYSICAL EXAMINATION; POLYMORPHIC VENTRICULAR TACHYCARDIA; PRIORITY JOURNAL; QT PROLONGATION; RESUSCITATION; ST SEGMENT DEPRESSION; SYSTOLIC HEART MURMUR; T WAVE INVERSION; THORAX PAIN; THORAX RADIOGRAPHY; TORSADE DES POINTES; UNSTABLE ANGINA PECTORIS; URINARY TRACT INFECTION; VOMITING;

EID: 84889090784     PISSN: 09753583     EISSN: 09762833     Source Type: Journal    
DOI: 10.1016/j.jcdr.2013.08.005     Document Type: Article

References (15)

1. G.M. Keating Ranolazine: a review of its use as add-on therapy in patients with chronic stable angina pectoris Drugs 73 2013 55 73
2. N. Hawwa, and V. Menon Ranolazine: clinical applications and therapeutic basis Am J Cardiovasc Drugs 13 2013 5 16
3. B.M. Scirica, D.A. Morrow, and H. Hod Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: results from the Metabolic Efficiency with Ranolazine for Less Ischemia in Non ST-Elevation Acute Coronary Syndrome Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) randomized controlled trial Circulation 116 2007 1647 1652
4. N. El-Sherif, and G. Turitto Torsade de pointes Curr Opin Cardiol 18 2003 6 13
5. R. Passman, and A. Kadish Polymorphic ventricular tachycardia, long Q-T syndrome, and torsades de pointes Med Clin North Am 85 2001 321 341
6. D.M. Roden Clinical practice. Long-QT syndrome N Engl J Med 358 2008 169 176
7. D.M. Roden Drug-induced prolongation of the QT interval N Engl J Med 350 2004 1013 1022
8. L.M. Hondeghem, and D.J. Snyders Class III antiarrhythmic agents have a lot of potential but a long way to go. Reduced effectiveness and dangers of reverse use dependence Circulation 81 1990 686 690
9. B.A. Liu, and D.N. Juurlink Drugs and the QT interval - caveat doctor N Engl J Med 351 2004 1053 1056
10. B.R. Chaitman, C.J. Pepine, and J.O. Parker Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial JAMA 291 2004 309 316
11. D.A. Morrow, B.M. Scirica, and E. Karwatowska-Prokopczuk Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial JAMA 297 2007 1775 1783
12. B.R. Chaitman Ranolazine for the treatment of chronic angina and potential use in other cardiovascular conditions Circulation 113 2006 2462 2472
13. D. Tzivoni, S. Banai, and C. Schuger Treatment of torsade de pointes with magnesium sulfate Circulation 77 1988 392 397
14. I.A. Khan Long QT syndrome: diagnosis and management Am Heart J 143 2002 7 14
15. D.P. Zipes, A.J. Camm, and M. Borggrefe ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death) J Am Coll Cardiol 48 2006 e247 e346